India makes 60% of the world's vaccines. The pandemic only made this dependency stronger.
When COVID-19 hit, the world expected Pfizer and Moderna to save it. Modern mRNA technology. American innovation. What actually happened was different. The Serum Institute of India produced more doses of COVID-19 vaccine than any other manufacturer on earth. Over 1.5 billion doses delivered to 170+ countries through COVAX. Most of Africa was vaccinated using Indian-manufactured Covishield, not Pfizer.
The pandemic didn't change India's role. It revealed how central it already was.
The Serum Institute alone produces 1.5 billion vaccine doses per year — more than Sanofi, GSK, and Merck combined. Bharat Biotech, Biological E, and Panacea Biotec add another billion-plus. India's six largest vaccine manufacturers cover diseases from polio to measles, hepatitis to HPV. Every UNICEF immunization campaign relies on Indian production.
Generic drugs follow the same pattern. India produces 40% of generic prescription drugs consumed in the United States. Dr. Reddy's, Sun Pharma, Cipla, and BioCon dominate antibiotic, antiviral, and oncology generics across Western markets. When Americans pay $4 for a generic at Walmart, that pill was likely made in Hyderabad or Mumbai.
The structural reasons are durable. India trained the largest pool of biotech talent outside China. It built world-class production infrastructure between 1990 and 2010. It enforces quality standards that satisfy FDA inspectors. The dependency isn't temporary cost advantage. It's two decades of compounding investment.
When the next pandemic hits, the same factories will be the bottleneck. Not labs in Boston or Basel.
